DBV Technologies Stock (NASDAQ:DBVT), Quotes and News Summary - Benzinga
DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021
Peanut Allergy Pipeline, FDA Approvals, Clinical Trials
DBV TECHNOLOGIES quote - Financial instrument overview - Euronext Paris
BCV lève 6 millions d'euros en Série A | Business Wire
DBV Technologies (@DBVTechnologies) / X
DBV Technologies (@DBVTechnologies) / X
DBV Technologies (@DBVTechnologies) / X
DBV Technologies (@DBVTechnologies) / X
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™
DBV Technologies (@DBVTechnologies) / X
DBV Technologies S.A. (DBVT) Stock Price, Quote & News - Stock Analysis
DBV Announces Promising 2-Year Results from Ongoing Viaskin “Peanut Patch” Toddler Study | SnackSafely.com
DBV Technologies (@DBVTechnologies) / X
DBV Technologies Stock (NASDAQ:DBVT), Quotes and News Summary - Benzinga
DBV Technologies S.A. (NASDAQ:DBVT) Q3 2023 Earnings Call Transcript
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document
EX-99.1
Unlocking the Powerful Immune Properties of the Skin to Deliver Innovative Treatments to Patients
Viaskin Peanut Patch: Lasting Response After Three Years | SnackSafely.com
